Neuromonics provides hearing healthcare professional across the United States, Australia and New Zealand with its world leading medical devices for the treatment of tinnitus. With a 90% success rate, compared with alternatives, Neuromonics’ product yields superior clinical outcomes, more quickly, more consistently, more efficiently through a treatment that is both more pleasant for the tinnitus sufferer and more attractive for the healthcare professional. Co-founded by Innovation Capital in late 2001, Neuromonics is now headquartered in Bethlehem, New Jersey.